-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Shisiyao Group issued an announcement saying that the group’s bromhexine hydrochloride injection (2ml: 4mg) for imitation of category 3 production was approved and deemed to have been reviewed, making it the second product of this product.
Companies that have been reviewed.
According to data from Meinenet, the sales of terminal bromhexine injections in China's public medical institutions have exceeded 2 billion yuan in recent years, and there has been a year-on-year decline in the first half of 2020.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
Companies that have been reviewed.
According to data from Meinenet, the sales of terminal bromhexine injections in China's public medical institutions have exceeded 2 billion yuan in recent years, and there has been a year-on-year decline in the first half of 2020.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
On March 25, 2021, the information of drug approval documents to be collected is released
Information, bromhexine hydrochloride injection is an expectorant drugs, mainly for chronic bronchitis and other respiratory diseases .
According to data from Menet.
com, in recent years , the sales of terminal bromhexine injections in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 2 billion yuan, with a year-on-year increase in the first half of 2020.
Decline.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
com, in recent years , the sales of terminal bromhexine injections in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 2 billion yuan, with a year-on-year increase in the first half of 2020.
Decline.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Currently, bromhexine injections include bromhexine hydrochloride injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride glucose injection.
Among them, bromhexine hydrochloride injection of new production companies have Double-Crane Pharmaceutical Resources, American and Konka Le Sichuan Pharmaceutical, Shijiazhuang four-drug and other six.
Among them, only Sichuan Meida Kangjiale Pharmaceutical Co.
, Ltd.
and Shijiazhuang Four Medicines have been evaluated.
In addition, the supplementary application for consistency evaluation of Hebei Renheyikang Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical is under review and approval, Jiangxi Yintao Pharmaceutical|Jiangxi Yiyou Pharmaceutical, Hebei Kaiwei Pharmaceutical|Guangzhou Poinsettia Pharmaceutical is a generic model The 3 types of submissions are under review and approval, and will be deemed as over-evaluated after approval.
Among them, bromhexine hydrochloride injection of new production companies have Double-Crane Pharmaceutical Resources, American and Konka Le Sichuan Pharmaceutical, Shijiazhuang four-drug and other six.
Among them, only Sichuan Meida Kangjiale Pharmaceutical Co.
, Ltd.
and Shijiazhuang Four Medicines have been evaluated.
In addition, the supplementary application for consistency evaluation of Hebei Renheyikang Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical is under review and approval, Jiangxi Yintao Pharmaceutical|Jiangxi Yiyou Pharmaceutical, Hebei Kaiwei Pharmaceutical|Guangzhou Poinsettia Pharmaceutical is a generic model The 3 types of submissions are under review and approval, and will be deemed as over-evaluated after approval.
Source: Official website of the State Food and Drug Administration, announcements of listed companies, Mynet database
A few days ago, Shisiyao Group issued an announcement saying that the group’s bromhexine hydrochloride injection (2ml: 4mg) for imitation of category 3 production was approved and deemed to have been reviewed, making it the second product of this product.
Companies that have been reviewed.
According to data from Meinenet, the sales of terminal bromhexine injections in China's public medical institutions have exceeded 2 billion yuan in recent years, and there has been a year-on-year decline in the first half of 2020.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
Companies that have been reviewed.
According to data from Meinenet, the sales of terminal bromhexine injections in China's public medical institutions have exceeded 2 billion yuan in recent years, and there has been a year-on-year decline in the first half of 2020.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
On March 25, 2021, the information of drug approval documents to be collected is released
Information, bromhexine hydrochloride injection is an expectorant drugs, mainly for chronic bronchitis and other respiratory diseases .
According to data from Menet.
com, in recent years , the sales of terminal bromhexine injections in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 2 billion yuan, with a year-on-year increase in the first half of 2020.
Decline.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
com, in recent years , the sales of terminal bromhexine injections in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 2 billion yuan, with a year-on-year increase in the first half of 2020.
Decline.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Currently, bromhexine injections include bromhexine hydrochloride injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride glucose injection.
Among them, bromhexine hydrochloride injection of new production companies have Double-Crane Pharmaceutical Resources, American and Konka Le Sichuan Pharmaceutical, Shijiazhuang four-drug and other six.
Among them, only Sichuan Meida Kangjiale Pharmaceutical Co.
, Ltd.
and Shijiazhuang Four Medicines have been evaluated.
In addition, the supplementary application for consistency evaluation of Hebei Renheyikang Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical is under review and approval, Jiangxi Yintao Pharmaceutical|Jiangxi Yiyou Pharmaceutical, Hebei Kaiwei Pharmaceutical|Guangzhou Poinsettia Pharmaceutical is a generic model The 3 types of submissions are under review and approval, and will be deemed as over-evaluated after approval.
Among them, bromhexine hydrochloride injection of new production companies have Double-Crane Pharmaceutical Resources, American and Konka Le Sichuan Pharmaceutical, Shijiazhuang four-drug and other six.
Among them, only Sichuan Meida Kangjiale Pharmaceutical Co.
, Ltd.
and Shijiazhuang Four Medicines have been evaluated.
In addition, the supplementary application for consistency evaluation of Hebei Renheyikang Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical is under review and approval, Jiangxi Yintao Pharmaceutical|Jiangxi Yiyou Pharmaceutical, Hebei Kaiwei Pharmaceutical|Guangzhou Poinsettia Pharmaceutical is a generic model The 3 types of submissions are under review and approval, and will be deemed as over-evaluated after approval.
Source: Official website of the State Food and Drug Administration, announcements of listed companies, Mynet database
A few days ago, Shisiyao Group issued an announcement saying that the group’s bromhexine hydrochloride injection (2ml: 4mg) for imitation of category 3 production was approved and deemed to have been reviewed, making it the second product of this product.
Companies that have been reviewed.
According to data from Meinenet, the sales of terminal bromhexine injections in China's public medical institutions have exceeded 2 billion yuan in recent years, and there has been a year-on-year decline in the first half of 2020.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
Companies that have been reviewed.
According to data from Meinenet, the sales of terminal bromhexine injections in China's public medical institutions have exceeded 2 billion yuan in recent years, and there has been a year-on-year decline in the first half of 2020.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
On March 25, 2021, the information of drug approval documents to be collected is released
Information, bromhexine hydrochloride injection is an expectorant drugs, mainly for chronic bronchitis and other respiratory diseases .
Disease disease disease According to data from Menet.
com, in recent years , the sales of terminal bromhexine injections in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 2 billion yuan, with a year-on-year increase in the first half of 2020.
Decline.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
Hospital hospital hospitalcom, in recent years , the sales of terminal bromhexine injections in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have all exceeded 2 billion yuan, with a year-on-year increase in the first half of 2020.
Decline.
Among them, Jiangxi Kelun Pharmaceutical has the largest market share, exceeding 25%; Shijiazhuang No.
4 Pharmaceuticals, Jincheng Hayes Pharmaceuticals, and Guangzhou Poinsettia Pharmaceuticals all account for more than 10% of the market.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Currently, bromhexine injections include bromhexine hydrochloride injection, bromhexine hydrochloride for injection, and bromhexine hydrochloride glucose injection.
Among them, bromhexine hydrochloride injection of new production companies have Double-Crane Pharmaceutical Resources, American and Konka Le Sichuan Pharmaceutical, Shijiazhuang four-drug and other six.
Among them, only Sichuan Meida Kangjiale Pharmaceutical Co.
, Ltd.
and Shijiazhuang Four Medicines have been evaluated.
In addition, the supplementary application for consistency evaluation of Hebei Renheyikang Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical is under review and approval, Jiangxi Yintao Pharmaceutical|Jiangxi Yiyou Pharmaceutical, Hebei Kaiwei Pharmaceutical|Guangzhou Poinsettia Pharmaceutical is a generic model The 3 types of submissions are under review and approval, and will be deemed as over-evaluated after approval.
Enterprise business enterpriseAmong them, bromhexine hydrochloride injection of new production companies have Double-Crane Pharmaceutical Resources, American and Konka Le Sichuan Pharmaceutical, Shijiazhuang four-drug and other six.
Among them, only Sichuan Meida Kangjiale Pharmaceutical Co.
, Ltd.
and Shijiazhuang Four Medicines have been evaluated.
In addition, the supplementary application for consistency evaluation of Hebei Renheyikang Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical is under review and approval, Jiangxi Yintao Pharmaceutical|Jiangxi Yiyou Pharmaceutical, Hebei Kaiwei Pharmaceutical|Guangzhou Poinsettia Pharmaceutical is a generic model The 3 types of submissions are under review and approval, and will be deemed as over-evaluated after approval.
Source: Official website of the State Food and Drug Administration, announcements of listed companies, Mynet database
